Martinez lab

Martinez Lab Picture

The Martinez & Teigen lab constitutes one of three labs in the Biorecognition group.

The Martinez & Teigen lab studies the relationship between molecular structure and function to understand human health and disease. We use a combination of computational and experimental techniques, within the fields of biophysics, biochemistry and cellular biology. We aim to develop new therapeutic options for inborn errors of metabolism, in particular Phenylketonuria and neurotransmitter disorders (e.g. tyrosine hydroxylase deficiency).

Permanent staff:

Professor Aurora Martinez
Professor Knut Teigen
Ming Ying, chief engineer

graphical abstract mol therapy

From molecule to medicine

Martinez and collaborators are developing a pharmacological chaperone therapy for acute intermittent porphyria

Full-length human PAH

The structure of the enzyme implicated in phenylketonuria (PKU)

The structure of full-length phenylalanine hydroxylase in complex with the cofactor BH4 is presented in the most recent issue of PNAS. As the cofactor is also used as a therapy for PKU, this structure is of medical importance.

Research news
Back cover of April 2019 issue of Human Mutation

Novel interaction of the co-chaperone DNAJC12 with phenylalanine hydroxylase variants

Researchers from the lab of Aurora Martinez describe a novel mechanism for the degradation of enzymes involved in phenylketonuria and other neurometabolic disorders.

Research communication
Glad barn spiser frukt

Our research on "molecular crutches" in the national media

In an article published in Aftenposten Viten, researcher Marte Innselset Flydal describes how she is planning to develop medicine for children suffering from the rare disease phenylketonuria.